Forward-Looking Statements

The presentations being made on May 25, 2022 include forward-looking statements concerning Baxter’s financial results, R&D pipeline, including planned product launches (many of which are subject to regulatory approval and may require additional investment) and results of clinical trials, business development activities (including anticipated cost and revenue synergies), capital structure, cost savings initiatives, Baxter’s long range plan (which includes financial outlook for 2022 and 2022-2025) and other growth strategies. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: the impact of global economic conditions (including the ongoing war in Ukraine and the related economic sanctions being imposed globally in response to the conflict and potential trade wars) and public health crises and epidemics, such as the ongoing coronavirus (COVID-19) pandemic, on the company and its employees, customers and suppliers, including foreign governments in countries in which the company operates; demand for and market acceptance of risks for new and existing products; product development risks (including satisfactory clinical performance and obtaining required regulatory approvals); product quality or patient safety concerns; continuity, availability and pricing of acceptable raw materials and component supply (including impacts from COVID-19); inability to create additional production capacity in a timely manner or the occurrence of other manufacturing or supply difficulties (including as a result of a natural disaster, public health crises and epidemics/pandemics, geopolitical crises, regulatory actions or otherwise); accurate identification of and execution on business development and R&D opportunities and realization of anticipated benefits (including the acquisitions of Cheetah Medical, Seprafilm Adhesion Barrier, specified OUS rights to Caelyx/Doxil, full U.S. and specific OUS rights to Transderm Scop, PerClot, Hillrom and certain rights to Zosyn in the U.S. and Canada); breaches or failures of Baxter’s information technology systems or products, including by cyberattack, unauthorized access or theft; the adequacy of Baxter’s cash flows from operations and other sources of liquidity to meet its ongoing cash obligations and fund its investment program; loss of key employees or inability to identify and recruit new employees; future actions of regulatory bodies and other governmental authorities, including FDA, the Department of Justice, the SEC, the New York Attorney General and foreign regulatory agencies, including the continued delay in lifting the warning letter at Baxter’s Ahmedabad facility; the outcome of pending or future litigation, including the opioid litigation and current and future ethylene oxide litigation or other claims; proposed regulatory changes of the U.S. Department of Health and Human Services in kidney health policy and reimbursement, which may substantially change the U.S. end-stage renal disease market and demand for the company’s peritoneal dialysis products, necessitating significant multiyear capital expenditures, which are difficult to estimate in advance; failures with respect to compliance programs; future actions of third parties, including payers; U.S. healthcare reform and other global austerity measures; pricing, reimbursement, taxation and rebate policies of government agencies and private payers; the impact of competitive products and pricing, including generic competition, drug reimportation and disruptive technologies; fluctuations in foreign exchange and interest rates; the ability to enforce owned or in-licensed patents or the prevention or restriction of the manufacture, sale or use of products or technology affected by patents of third parties; global, trade and tax policies; any change in laws concerning the taxation of income (including current or future tax reform), including income earned outside the United States and potential taxes associated with the Base Erosion and Anti-Abuse Tax or the Build Back Better framework; actions taken by tax authorities in connection with ongoing tax audits; and other risks identified in Baxter’s most recent filing on Form 10-K and other Securities and Exchange Commission filings, all of which are available on Baxter’s website. Baxter does not undertake to update its forward-looking statements.
WE EMPOWER CAREGIVERS BY CONNECTING EVERY MOMENT OF CARE
Global Market Expected To Grow 6% - 7% Through 2025

**Market Dynamics**

**Opportunities**
- Providers investing to synchronize care communications across their networks
- Bed market growth tied to desire for clinically relevant technology updates, deeper patient insights, and enhanced patient safety
- Hospitals investing to upgrade surgical equipment to improve revenue generation potential, especially post-COVID
- Hospital customers increasingly value workflow efficiency solutions to combat staff shortages

**Challenges**
- Potential near-term capital budget constraints

<table>
<thead>
<tr>
<th>Category</th>
<th>2022E</th>
<th>2025E</th>
</tr>
</thead>
<tbody>
<tr>
<td>Care Communications</td>
<td>~$2.9B</td>
<td>~$4.6B</td>
</tr>
<tr>
<td>Surgical Solutions</td>
<td>~$4.2B</td>
<td>~$4.8B</td>
</tr>
<tr>
<td>Tech Service SmartCare</td>
<td>~$1.3B</td>
<td>~$1.4B</td>
</tr>
<tr>
<td>Patient Supports &amp; Beds</td>
<td>~$4.4B</td>
<td>~$4.8B</td>
</tr>
<tr>
<td>CAGR 6% - 7%</td>
<td>~$13B</td>
<td>~$16B</td>
</tr>
</tbody>
</table>

**Patient Supports & Beds**
- 2% - 3%

**Care Communications**
- 16% - 18%

**Surgical Solutions**
- 4% - 5%

**Tech Service SmartCare**
- 2% - 3%
Market-Leading Portfolio

**Patient Supports & Beds**
Enhancing connected patient supports to help optimize outcomes with innovative technologies

- Centella Smart+ Bed
- Progressa Smart+ Bed
- Liko Patient Lifts

**Surgical Solutions**
Enabling peak procedural performance and connectivity

- TS7000 Robotic Table
- iLED7 Surgical Light
- FCS Equipment Booms

**Care Communications**
Connecting care teams inside and outside of the hospital to help improve patient care

- Voalte Nurse Call
- Voalte Mobile
- MDI / Alert & Alarm Management

**Technical Service & SmartCare**
Protecting patients with proactive service solutions

- Maintenance & Repair Services
- Remote Device Management
- Technical Training

FY 2021 Revenue $1.9B

Market-Leading Portfolio 61% 13% 10% 16%

Care Communications

Patient Supports & Beds

Surgical Solutions

Enhancing connected patient supports to help optimize outcomes with innovative technologies

- Centella Smart+ Bed
- Progressa Smart+ Bed
- Liko Patient Lifts

Enabling peak procedural performance and connectivity

- TS7000 Robotic Table
- iLED7 Surgical Light
- FCS Equipment Booms

Protecting patients with proactive service solutions

- Maintenance & Repair Services
- Remote Device Management
- Technical Training
Strategy To Drive In-Line Market Growth Of 6% - 7% Through 2025

**Innovation**

**Connected Care:**
- Expand smart patient support device portfolio across all care areas
- Harmonize comprehensive Care Communications and patient insights platform
- Deliver new solutions that address key customer needs

**Market Expansion**

**Geographic Expansion:**
- Optimize global portfolio and go-to-market strategy
- Deliver right-sized connectivity model for each region

**Market Development:**
- Become a partner of choice to hospitals
- Invest in clinical efficiency and outcomes evidence

**Operational Efficiency**

**Drive Efficiencies:**
- Enhance implementation speed
- Address near-term product backlog and component sourcing challenges
- Drive improved profitability through portfolio rationalization and manufacturing footprint optimization
Connected Care Solutions Drive Growth

40%+
Connected Care Revenue
2021 PSS & GSS revenue from devices or software that can collect, analyze, and/or communicate data to help transform healthcare

~2x
Connected Care Revenue Growth
Expected growth versus non-connected portfolio in 2022
Innovation Pipeline To Drive Improved Patient Outcomes And Workflow Efficiencies

**Recent Launches**

- **“Smart” Devices**
  - Centrella Smart+ Bed with CFCM
  - PST 500 Precision Surgical Table
  - TS7000dV Robotic Surgical Table Update

- **Decision Support & Analytics**
  - Voalte Alert & Alarm Management
  - Precision Locating System

- **Simplified Clinical Communications**
  - Voalte Nurse Call
  - Helion Procedural Integration

**Near Term Launches**

- **“Smart” Devices**
  - Next Gen ICU Smart+ Bed Platform

**Future Launches**

- **Virtual Care Solution**
  - Advanced Patient Data Visualization
  - Voalte Mobile Comm App
Care Communications Transforming Healthcare Delivery

Communication Interfaces
- Nurse Call System
- Mobile Communications
- Patient & Family Engagement
- Efficiency & Safety Reports

Communication Platform Services
- EMR Connectivity
- Medical Device Integration
- Collaboration Services
- Video Streaming Services
- Schedule Management
- Clinical Insights Engine
- Alert & Alarm Management
- Assignment Management

Connected In-Room Equipment
- Smart+ Beds
- Monitoring Equipment
- Infusion Pump (example)

Current Offering

Near Term Launches

Connecting Baxter Equipment
• Positioned to be a critical partner for every hospital, worldwide
• Industry leading portfolio of connected solutions empower care teams to improve care
• Connectivity platform will enable accelerated connectivity of the Baxter portfolio
2022 Investor Conference